Jeff Meacham

are there other I-O combo mechanisms that could also bear fruit, or is that better addressed with the rest of your oncology pipeline

I was curious if your pipeline evaluation process has evolved just to look at maximizing ROI on your R&D investments

are there settings where an IV modality is perhaps a better fit in the clinical practice?

on Povi, congrats on the quick filing in IgAN, but looking beyond PMN and gMG, is it worth it to do a basket study?